Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. October 26, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.01914 Journal of Clinical Oncology - published online before print October 26, 2022 PMID: 36288506 Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations Warren P. Mason , MD1xWarren P. MasonSearch for articles by this author Show More 1Princess Margaret Cancer Centre, Toronto, ON, Canada https://doi.org/10.1200/JCO.22.01914 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFocal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 MutationsThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Warren P. MasonHonoraria: Bayer, Viatris, Inc, Apotex, Inc, GlaxoSmithKlineExpert Testimony: MedcanNo other potential conflicts of interest were reported. Companion Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations